In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

AC Immune SA cofounder and CEO Andrea Pfeifer offers lessons in strategy and resilience for building and maintaining a drug ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and ...

On a recent episode of the Business of Biotech podcast, Brian Lortie, president and CEO of Uniquity Bio, offered up useful advice about the complex process of building and leading a biotech startup in ...

In most life sciences companies, commercial teams are pulled into BD conversations, but often the depth of evaluation falls short of making real impact. By the time we’re asked to weigh in, key ...

In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

GenVoy-ILM™ T cell Kit for mRNA is a lipid nanoparticle (LNP) reagent mix optimized for the delivery of mRNA or CRISPR Cas9 mRNA with gRNA into human primary T cells using LNPs prepared on the ...